1018 - cd97 is a critical regulator of acute myeloid leukemia stem cell function

Despite advances in our understanding of the genetic origins of acute myeloid leukemia (AML), treatment options have remained essentially unchanged for 30 years, and clinical outcomes remain poor. AML is maintained by leukemia stem cells (LSCs), which are critical for disease maintenance as well as re-initiating disease after therapy. We previously identified novel markers and therapeutic targets in AML and MDS by comparing the transcriptomes of stem cells to normal purified HSCs, leading to the identification of CD99 as an antigen selectively expressed on LSCs.  Moreover, novel monoclonal antibodies against CD99 exerted significant cytotoxic effects against AML and MDS stem cells.  Recently, we identified CD97 as an antigen expressed in the vast majority of human AMLs.

Source: Experimental Hematology - July 31, 2019 Category: Hematology Authors: Christopher Park, Gaelle Martin, Nainita Roy, Sohini Chakraborty, Alexis Desrichard, Stephen chung, Carolien Woolthuis, Wenhuo Hu, Iryna berezniuk, Francine Garrett-Bakelman, Jorg Hamann, sean Devlin, Timothy chan Source Type: research